Current Status, Position
Prof Dr Steven Simoens is a Professor of health economics.
Prof Dr Steven Simoens is a Commercial Engineer (KU Leuven, 1997), who later specialised in health economics and obtained a MSc in Health Economics (University of York, 1998) and a PhD in Economics (University of Aberdeen, 2001).
The research interests of Steven Simoens focus on health economic aspects of medicinal products. Steven Simoens has carried out numerous cost(-of-illness) analyses, economic evaluations and budget impact analyses of medicinal products. He has also worked extensively in the area of policy relating to market access of medicinal products, with a particular interest in oncology, orphan, generic and biosimilar medicinal products, and shortages of medicinal products.
Conflict of interest: Prof Dr Steven Simoens is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). He was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD, and he has participated in advisory board meetings for Amgen, Pfizer and Sandoz. He has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer; and he has had speaking engagements for Amgen, Celltrion and Sandoz. He is member of the leadership team of the ISPOR Special Interest Group on Biosimilars.